BioSpace News Archive

Corcept Therapeutics Incorporated (NASDAQ: CORT), today announced that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer will be featured in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced they have entered into a distribution agreement with SeaSpine® Orthopedics Corporation, a wholly-owned subsidiary of SeaSpine Holdings Corporation, to exclusively distribute the 7D Surgical FLASH™ Navigation platform for pediatric applications.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced that management will present at the following investor conferences in September.

Rezolute, Inc. (Nasdaq: RZLT), today announced that it has begun dosing patients in the second cohort of its Phase 2b clinical trial of RZ358 (RIZE).

Lyra Therapeutics, Inc. (Nasdaq: LYRA), today announced that preclinical data for XTreo™ were published online in the peer-review journal, American Journal of Rhinology & Allergy.

Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced the additions of Ronald W. Barrett, Ph.D., and Alana McNulty as members of the Company’s Board of Directors.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the Baird 2021 Global Healthcare Conference.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare.

BioCardia®, Inc. (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference.

Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will participate in a virtual panel discussion at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13-15, 2021.